Chordate

Chordate sums up H1 and projects sales growth

It has been an eventful first half of the year for Chordate Medical, including a list change to Nasdaq First North and an ongoing...
Köping Hockey Player safety

Köping Hockey Chairman puts player safety first

Köping Hockey is a third tier ice hockey team in Sweden, and its players do not get the same benefits as those in top...
Evaxion Lung Cancer

Evaxion Biotech expands its programme with a new indication

Danish Evaxion Biotech, which develops AI-based immunotherapies, has seen encouraging preclinical results with the candidate EVX-03. The company is therefore expanding its programme to...
Alligator Bioscience's new CMO

Alligator Bioscience’s new CMO

Lund-based Alligator Bioscience has several projects in its pipeline, two of which are in the clinical phase. To keep the focus on development, the...
Sensidose

Sensidose’s CEO looks towards autumn after strong growth

Sensidose can greet the halfway point of 2022 with a strong cash position after its listing on Spotlight and rising sales despite a shortage...
New IR force at Cyxone

New IR force at Cyxone

In June, biotech Cyxone announced a change of management – Carl-Magnus Högerkorp stepped up from his role as Chief Operating Officer to also take...
Annexin RVO

Annexin wants to treat the inconspicuous eye disease

Retinal vein occlusion, RVO, is one of the most common causes of vision loss in the world - yet it is unknown to many....
PhaseHolographic Bokslutskommuniké

Doubled sales and an improved position for PHI

In the year-end report for 2021/2022, Phase Holographic Imaging highlights the increased sales, the investment in regenerative medicine and the patent awarded for synthetic...
Spago Nanomedical progressestowards clinical phase with Tumorad

Spago Nanomedical progresses towards clinical phase with Tumorad

Just before mid-year, Lund-based Spago Nanomedical announced that the company raised 58.4 MSEK in the completed capital round. The proceeds give the company the...
Pila Pharma starts studies

Pila Pharma initiates toxicological studies

Malmö company Pila Pharma is in full swing with preparations for a phase IIb study with the drug candidate XEN-D0501. But before the study...